dipyridamole has been researched along with Maxillary Neoplasms in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Maxillary Neoplasms: Cancer or tumors of the MAXILLA or upper jaw.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sato, S | 1 |
| Kohno, K | 1 |
| Hidaka, K | 1 |
| Hisatsugu, T | 1 |
| Kuwano, M | 1 |
| Komiyama, S | 1 |
1 other study available for dipyridamole and Maxillary Neoplasms
| Article | Year |
|---|---|
Differentially potentiating effects by dipyridamole on cytotoxicity of 5-fluorouracil against three human maxillary cancer cell lines derived from a single tumor.
Topics: Cell Survival; Dipyridamole; Drug Synergism; Fluorodeoxyuridylate; Fluorouracil; Humans; Maxillary N | 1993 |